Moderna has delayed its break-even goal by two years, pushing it to 2028, due to slower regulatory processes for key products like flu and cancer vaccines. The company expects lower sales in 2025 compared to this year and plans cost-saving measures, including cuts in research and development.
| Subscribe To Our Free Newsletter |
